Outlook Therapeutics Inc.

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology and retinal diseases. The company develops and commercializes LYTENAVA (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab designed for use in retinal indications such as wet age-related macular degeneration. Its product work centers on ONS-5010, a monoclonal antibody candidate intended to address unmet needs in the treatment of retinal vascular disorders. Outlook Therapeutics operates in the specialty eye-care segment of the pharmaceutical market, where biologic therapies are used to support vision-related conditions affecting the retina. The company’s current business is built around advancing and commercializing this ophthalmic anti-VEGF therapy across regulated markets for patients with serious retinal diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Robert Charles Jahr

Employees

17

Headquarters

Iselin, NJ, United States

Website

outlooktherapeutics.com